Clinical trials: Alcoholism
Alcohol Dependence
Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent
Examination of the effect of GET 73 on alcohol pharmacokinetics and pharmacodynamics (intoxication and sedation)and safety profile in alcohol-dependent individuals.To evaluate whether GET 73, as compared to placebo, results in…
- Trial name
- SPAD (NCT01842503)
- Testing
- GET 73, inactive ingredients capsule
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Laboratorio Farmaceutico Ct S.r.l.
Alcoholism
Trial Investigating the Efficacy and Safety of SCH 900435 (Org 25935) in Relapse Prevention in Participants With Alcohol Dependence (P05718)
The purpose of this study is to assess the effects of SCH 900435 (Org 25935, MK-8435) on heavy drinking, safety and tolerability of SCH 900435 in participants with alcohol dependence.
- Trial name
- OD-H (NCT00764660)
- Testing
- SCH 900435
- Volunteers
- 141 people
- Sponsor
- Merck Sharp & Dohme LLC
Alcohol Addiction
Soberlink - MAP Outcomes Study Protocol
The purpose of this study is to show the effectiveness of Soberlink's remote alcohol monitoring system integrated with MAP's patient engagement platform (EHR) to monitor a sample size of at-risk alcohol use disorder (AUD)…
- Trial name
- NCT03190356
- Testing
- Soberlink Cellular Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Soberlink Healthcare LLC
Alcoholism
GSK1521498 Alcohol Interaction Study
The aim of the study is to assess the safety and tolerability of GSK1521498 in combination with alcohol and to determine the amount of GSK1521498 and alcohol in your blood after you have been given these together.
- Trial name
- NCT01366573
- Testing
- GSK1521498
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Substance Dependence
EtOH Interaction Study
This study will investigate the possible effects of alcohol in combination with GSK598809 on the central nervous system in 20 healthy male and female volunteers, between 18 and 65 years of age.
- Trial name
- NCT00887367
- Testing
- GSK598809, Ethanol
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcoholism
ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults
This was a Phase 3, multi-center extension of Alkermes' Study ALK21-003EXT (NCT01218971) to further assess the long-term safety of repeat monthly doses of Medisorb® naltrexone (VIVITROL®).
- Trial name
- NCT00156923
- Testing
- Medisorb naltrexone 380 mg, Medisorb naltrexone 190 mg
- Volunteers
- 108 people
- Sponsor
- Alkermes, Inc.
Alcohol Dependence
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
This was a study of the effects of VIVITROL® on alcohol cue-induced craving and the associated brain activation patterns in alcohol-dependent adults who had recently completed alcohol detoxification and were seeking further…
- Trial name
- NCT00511836
- Testing
- VIVITROL 380 mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Alkermes, Inc.
Alcoholism
ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted in subjects diagnosed with alcohol dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.
- Trial name
- NCT01218958
- Testing
- Medisorb naltrexone 190 mg, Medisorb naltrexone 380 mg
- Volunteers
- 624 people
- Sponsor
- Alkermes, Inc.
Alcoholism
Alcohol Interaction Study
The purpose of this study is understand the effects of GSK114814 and alcohol in healthy volunteers when taken together.
- Trial name
- NCT01181908
- Testing
- single dose
- Where
- Netherlands
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcoholism
To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
A total of at least 48 healthy subjects with a history of social drinking will be recruited into this single-centre, randomized, double-blind, cross-over study.
- Trial name
- NCT01738867
- Testing
- GSK1521498, Naltrexone (NTX)
- Where
- United Kingdom
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alcohol Dependence
A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects
The safety, tolerability, and pharmacokinetics of nalmefene at a single oral dose of 10 mg in healthy Japanese male subjects will be evaluated.
- Trial name
- NCT02679469
- Testing
- nalmefene hydrochloride 10 mg
- Where
- Japan
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Addictive Behavior, Alcohol Use Disorder
90-Day Online Substance Use Program
Individuals indicating risky substance use are randomly assigned either to a three-month online intervention on the Workit Health platform or a waitlist/treatment as usual.
- Conditions
- Addictive Behavior, Alcohol Use Disorder, Alcohol Abuse, Drug Abuse
- Trial name
- NCT03069118
- Testing
- Treatment - Workit Health Online Program, Control - Resource List
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Workit Health
Alcohol Dependence
Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care
To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care
- Trial name
- NCT02195817
- Testing
- Selincro® 18 mg with continuous psychosocial support: Cohort A, Initial psychosocial support: Cohort B
- Where
- 48 sites in France, Germany and 2 more
- Volunteers
- 378 people
- Sponsor
- H. Lundbeck A/S
Alcoholism
A Study of LY2940094 in Participants With Alcohol Dependency
The main purpose of this study is to evaluate a once daily (QD) 40-milligram (mg) oral dose of LY2940094 in participants with an alcohol dependency to evaluate if LY2940094 will reduce alcohol drinking in these participants.
- Trial name
- NCT01798303
- Testing
- LY2940094
- Where
- 5 sites in United States
- Volunteers
- 88 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Alcohol Consumption, Alcohol Abuse
Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer
The goal of the proposed research is to complete the development of a web-based program to train Employee Assistance Program (EAP) and EAP-affiliated managed behavioral health organization (MBHO) practitioners to conduct…
- Trial name
- BigAl2 (NCT02489032)
- Testing
- SBIRT Training & Support Tool, Waitlist Control
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Oregon Center for Applied Science, Inc.
Alcohol Use Disorder
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder
This study will determine the maximum tolerated dose (MTD) of arbaclofen placarbil (AP) in the treatment of subjects with Alcohol Use Disorder (AUD). For every two subjects receiving AP, one subject will receive placebo.
- Trial name
- NCT02511886
- Testing
- Arbaclofen Placarbil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indivior Inc.
Alcohol Use Disorder
Acamprosate Initiated During Alcohol Detoxification
Acamprosate is approved by the Food and Drug Administration (FDA) for the treatment of alcoholism. The purpose of this study is to see if initiating acamprosate early in alcohol detoxification instead of waiting until…
- Trial name
- NCT00360594
- Testing
- Acamprosate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Forest Laboratories
Alcohol Dependence
Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use
The purpose of this study is to explore the treatment effects of Selincro in alcohol dependent patients with liver impairment.
- Trial name
- NCT02197598
- Testing
- nalmefene
- Where
- 3 sites in Germany
- Volunteers
- 45 people
- Sponsor
- H. Lundbeck A/S
Alcoholism, Alcohol Dependence
Usability Study for SOBERLINK System
The Soberlink Cellular device, in its original packaging, along with the QuickStart guide will be provided to the end user in a simulated home use environment or by Rx in clinic.
- Trial name
- NCT02650180
- Testing
- Soberlink Cellular Device
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Soberlink Healthcare LLC
Mental Health
An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting
Innerview can address some of the challenges of integrating mental health and primary care by accurately and reliably collecting mental health evidence and activities directly from patients, and then organizing and automating…
- Trial name
- NCT02025647
- Where
- 5 sites in United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Pearson/Clinical Assessment